Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Finance

All eyes on new modality launches, cancer and rare disease data in 3Q19

Investors to watch new modality launches and cancer and rare disease data in a light 3Q19

June 29, 2019 12:47 AM UTC

While the typical summer lull means fewer catalysts in the third quarter, investors will be keeping a close eye on launches of new modality drugs.

Of special interest to multiple buysiders is the launch of SMA gene therapy Zolgensma onasemnogene abeparvovec-xioi from the AveXis Inc. unit of Novartis AG, which could be the first litmus test of gene therapy's commercial potential. ...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article